Wen Ye1, Michael Brandle2, Morton B Brown1, William H Herman3,4. 1. 1 Department of Biostatistics, University of Michigan , Ann Arbor, Michigan. 2. 2 Division of Endocrinology and Diabetes , Kantonsspital St. Gallen, St. Gallen, Switzerland . 3. 3 Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan. 4. 4 Department of Epidemiology, University of Michigan , Ann Arbor, Michigan.
Abstract
OBJECTIVES: The aim of this study was to develop and validate a computer simulation model for coronary heart disease (CHD) in type 2 diabetes mellitus (T2DM) that reflects current medical and surgical treatments. RESEARCH DESIGN AND METHODS: We modified the structure of the CHD submodel in the Michigan Model for Diabetes to allow for revascularization procedures before and after first myocardial infarction, for repeat myocardial infarctions and repeat revascularization procedures, and for congestive heart failure. Transition probabilities that reflect the direct effects of medical and surgical therapies on outcomes were derived from the literature and calibrated to recently published population-based epidemiologic studies and randomized controlled clinical trials. Monte Carlo techniques were used to implement a discrete-state and discrete-time multistate microsimulation model. Performance of the model was assessed using internal and external validation. Simple regression analysis (simulated outcome=b(0)+b(1)×published outcome) was used to evaluate the validation results. RESULTS: For the 21 outcomes in the six studies used for internal validation, R(2) was 0.99, and the slope of the regression line was 0.98. For the 16 outcomes in the five studies used for external validation, R(2) was 0.81, and the slope was 0.84. CONCLUSIONS: Our new computer simulation model predicted the progression of CHD in patients with T2DM and will be incorporated into the Michigan Model for Diabetes to assess the cost-effectiveness of alternative strategies to prevent and treat T2DM.
OBJECTIVES: The aim of this study was to develop and validate a computer simulation model for coronary heart disease (CHD) in type 2 diabetes mellitus (T2DM) that reflects current medical and surgical treatments. RESEARCH DESIGN AND METHODS: We modified the structure of the CHD submodel in the Michigan Model for Diabetes to allow for revascularization procedures before and after first myocardial infarction, for repeat myocardial infarctions and repeat revascularization procedures, and for congestive heart failure. Transition probabilities that reflect the direct effects of medical and surgical therapies on outcomes were derived from the literature and calibrated to recently published population-based epidemiologic studies and randomized controlled clinical trials. Monte Carlo techniques were used to implement a discrete-state and discrete-time multistate microsimulation model. Performance of the model was assessed using internal and external validation. Simple regression analysis (simulated outcome=b(0)+b(1)×published outcome) was used to evaluate the validation results. RESULTS: For the 21 outcomes in the six studies used for internal validation, R(2) was 0.99, and the slope of the regression line was 0.98. For the 16 outcomes in the five studies used for external validation, R(2) was 0.81, and the slope was 0.84. CONCLUSIONS: Our new computer simulation model predicted the progression of CHD in patients with T2DM and will be incorporated into the Michigan Model for Diabetes to assess the cost-effectiveness of alternative strategies to prevent and treat T2DM.
Authors: Milton C Weinstein; Bernie O'Brien; John Hornberger; Joseph Jackson; Magnus Johannesson; Chris McCabe; Bryan R Luce Journal: Value Health Date: 2003 Jan-Feb Impact factor: 5.725
Authors: Jason H Cole; Ellis L Jones; Joseph M Craver; Robert A Guyton; Douglas C Morris; John S Douglas; Ziyad Ghazzal; William S Weintraub Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams Journal: Lancet Date: 2007-09-08 Impact factor: 79.321
Authors: Natalia Olchanski; David van Klaveren; Joshua T Cohen; John B Wong; Robin Ruthazer; David M Kent Journal: Acta Diabetol Date: 2021-01-30 Impact factor: 4.280
Authors: Shihchen Kuo; Wen Ye; Mary de Groot; Chandan Saha; Jay H Shubrook; W Guyton Hornsby; Yegan Pillay; Kieren J Mather; William H Herman Journal: Diabetes Care Date: 2021-02-19 Impact factor: 19.112
Authors: Wen Ye; Shihchen Kuo; Edith C Kieffer; Gretchen Piatt; Brandy Sinco; Gloria Palmisano; Michael S Spencer; William H Herman Journal: Diabetes Care Date: 2021-05-06 Impact factor: 19.112
Authors: Nasuh C Büyükkaramikli; Maureen P M H Rutten-van Mölken; Johan L Severens; Maiwenn Al Journal: Pharmacoeconomics Date: 2019-11 Impact factor: 4.981